



## COMPANY OVERVIEW

GRI Bio, Inc. (NasdaqCM:GRI) is a pharmaceutical company specializing in developing treatments for inflammatory, fibrotic, and autoimmune diseases using Natural Killer T (NKT) cell modulators. Their strategic approach consists of a lead program entering Phase 2 for Idiopathic Pulmonary Fibrosis (IPF), a second program targeting Systemic Lupus Erythematosus (SLE), and additional early-phase development programs. The leadership team is filled with industry experts, including CEO Marc Hertz, Ph.D., with extensive executive, operational, and R&D experience in the biotech industry, CSO Vipin Kumar, Ph.D., an internationally renowned NKT cell researcher, and CMO Albert Agro, Ph.D., bringing a successful track record of 20+ years in drug development.

The technology and approach of GRI Bio focus on targeting the early drivers of inflammation, offering the potential for disease interruption and progression control. Leveraging selective immunomodulation by regulating NKT cells gives them a competitive advantage in treating inflammatory and fibrotic conditions. Their pipeline is further strengthened by a library of over 500 proprietary compounds.

A significant market opportunity lies in IPF, an orphan indication with around 40,000 new diagnoses annually, and SLE, a high-need area with limited treatment options.

## KEY CONSIDERATIONS

- GRI Bio is dedicated to developing new medicines for fibrotic diseases where dysregulated immune responses drive excessive scarring and organ damage. The company's lead indication is idiopathic pulmonary fibrosis (IPF).
- In addition to fibrosis, GRI Bio has preclinical programs focused on major autoimmune diseases, including systemic lupus erythematosus (SLE), multiple sclerosis, and inflammatory bowel disease.
- GRI Bio's first medicine, GRI-0621, an NKT antagonist program, is entering Phase 2 trials in 2023.
- With multiple clinical trial results over the next 18 months, GRI Bio expects its drug programs to hit key milestones that can increase the company's value for investors.

# GRI BIO - PURSUING TREATMENTS FOR DEVASTATING AUTOIMMUNE DISEASES

GRI Bio's drugs act on NKT cells in the immune system to "reset" faulty immune responses that drive fibrotic and autoimmune diseases.

## TARGETING FIBROSIS

GRI Bio is developing medicines to stop fibrosis progression and restore organ function.

## TUNING THE IMMUNE SYSTEM

GRI Bio is advancing a lupus program using NKT cell modulators to precisely tune faulty immune responses and significantly improve patients' lives.

## MODULATING NKT IMMUNE CELLS

GRI Bio's drugs act on NKT cells to "reset" faulty immune responses driving fibrotic and autoimmune disease.

## LUNG DISEASE DRUG ENTERING TRIALS

GRI Bio's lead drug for a rare lung disease called IPF is entering Phase 2 trials in 2023.

## EXPERIENCED DRUG DEVELOPMENT TEAM

GRI Bio's team includes experts in clinical development and immunology. Their expertise reduces execution risk.

## UPCOMING MILESTONES

Multiple clinical trial results over the next 18 months can increase GRI Bio's value.

# TARGETING THE IMMUNE SYSTEM TO TREAT DISEASE

GRI Bio is an emerging biopharmaceutical company developing novel immunotherapies that modulate Natural Killer T (NKT) cells, a key regulator of immune responses. By selectively “resetting” NKT cells, GRI aims to treat inflammatory, fibrotic, and autoimmune diseases that occur when the immune system malfunctions.

The company’s lead asset, GRI-0621, inhibits NKT cells to potentially halt lung fibrosis progression in idiopathic pulmonary fibrosis (IPF). IPF is a chronic, fatal disease affecting over 40,000 patients annually in the US. GRI-0621 is entering Phase 2 testing in 2023, with data expected in 2024.

GRI’s second program, GRI-0803, activates anti-inflammatory NKT cells and is initially targeted at systemic lupus erythematosus (SLE), an autoimmune disorder impacting over 160,000 Americans. GRI-0803 is set to begin first-in-human trials in 2024.

Additional earlier-stage candidates focus on diseases like primary sclerosing cholangitis, multiple sclerosis, and rheumatoid arthritis. GRI has robust patent coverage on its lead candidates extending to at least 2032, with potential for exclusivity out to 2038 and beyond based on orphan drug and novel chemical entity exclusivity periods.

Backed by a seasoned leadership team with proven drug development expertise, GRI leverages its deep understanding of NKT biology to address underserved patient populations. Its library of 500+ proprietary compounds provides a rich pipeline source.

With upcoming milestones, GRI is poised to clinically validate modulation of NKT cells as a breakthrough approach to treating a spectrum of immune-mediated illnesses. Successful proof-of-concept would cement GRI’s leadership in next-generation immunotherapies.

500+

Proprietary Compounds

100+ YEARS

Management experience

160,000

US SLE Patients

8

Preclinical and clinical programs

# LEADERSHIP



**MARC HERTZ, PHD**  
**CHIEF EXECUTIVE OFFICER**

- 20+ YEARS IMMUNOTHERAPY EXPERIENCE (FIBROSIS, INFLAMMATION, AUTOIMMUNITY, ALLERGY AND ONCOLOGY)
- DRUG DISCOVERY THROUGH PHASE 3
- C-LEVEL AND BOARD POSITIONS AT PHARMEXA, MULTIMERIC BIOTHERAPEUTICS, GEMVAX & EVOZYM



**VIPIN KUMAR, PHD**  
**CSO AND PROFESSOR AT UCSD**

- INTERNATIONALLY RECOGNIZED LEADER IN NKT CELL RESEARCH, REGULATION AND AUTOIMMUNITY
- ACADEMIC APPOINTMENTS AT UCSD, UCLA, LA JOLLA INSTITUTE FOR ALLERGY & IMMUNOLOGY
- PUBLISHED MORE THAN 130 PEER-REVIEWED ARTICLES



**ALBERT AGRO, PHD**  
**CHIEF MEDICAL OFFICER**

- 20+ YEARS IN DRUG DEVELOPMENT; CEO SUBLIMITY THERAPEUTICS
- INSTRUMENTAL ROLE AS C-LEVEL EXECUTIVE IN \$624 MILLION SALE OF CYNAPSUS TO SUNOVION IN 2016
- FILED AND FDA APPROVAL OF 7 NDAS, 40 INDS, 30 CTAS



**LEANNE KELLY**  
**CHIEF FINANCIAL OFFICER**

- 20+ YEARS FINANCIAL EXECUTIVE LEADING PRIVATE AND PUBLIC LIFE SCIENCE, TECHNOLOGY, AND E-COMMERCE COMPANIES
- STRONG BACKGROUND IN HEALTHCARE FINANCE AND ACCOUNTING
- AUDIT AND ADVISORY EXPERIENCE